{"id":390295,"date":"2019-12-27T00:00:00","date_gmt":"2019-12-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0008-2019-biopharma-systemic-lupus-erythematosus-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-29T05:24:24","modified_gmt":"2026-04-29T05:24:24","slug":"dlsfim0008-2019-biopharma-systemic-lupus-erythematosus-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0008-2019-biopharma-systemic-lupus-erythematosus-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Systemic Lupus Erythematosus | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>Systemic lupus erythematosus (<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be highly variable between patients. To date, the approval of Benlysta in 2011 is the most notable development in the\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0market following the failure of several promising therapies to pass their Phase III programs. However, Benlysta\u2019s modest efficacy is a major deterrent to its uptake. The unmet need remains high for effective\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0therapies, and several pharmaceutical companies are attempting to enter this market with multiple pending molecules. As these new\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0therapies seek to launch, the Disease Landscape and Forecast provides detailed analyses into current medical practice, key unmet needs, and new developments in the\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0space, along with an analysis of opportunities and obstacles faced by emerging agents.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How large is the treatable\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0population, and how will diagnosis \/ drug-treatment rates change over the 2018-2028 forecast period?<\/li>\n<li>What is the current state of\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0treatment? Which are the most important drugs and why? What are interviewed experts\u2019 insights on current treatment options? What are the key unmet needs in\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>?<\/li>\n<li>Which novel therapies are most promising and what sales \/ uptake could they secure in\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>? What therapies of note are progressing in earlier phases?<\/li>\n<li>What are the drivers and constraints in the\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><strong>Markets covered:\u00a0<\/strong>United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:<\/strong>\u00a0Approximately 16 country-specific interviews with <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854610582936537080567\">rheumatologists<\/gwmw> and <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854610582942245774738\">nephrologists<\/gwmw>.<\/p>\n<p><strong>Epidemiology:<\/strong>\u00a0Diagnosed prevalence of\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0by country and <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854610661680558364057\">subpopulations<\/gwmw> (<gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854610661688314979697\">nonrenal<\/gwmw>\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0and lupus nephritis).<\/p>\n<p><strong>Population segments in market forecast:<\/strong>\u00a0Total population, <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854610682604698156998\">nonrenal<\/gwmw>\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0population, renal\u00a0<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>\u00a0(<abbr title=\"lupus nephritis\">LN<\/abbr>) population.<\/p>\n<p><strong>Emerging therapies:\u00a0<\/strong>Phase II: 16 drugs; Phase III: 5 drugs.<\/p>\n","protected":false},"template":"","class_list":["post-390295","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-systemic-lupus-erythematosus","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390295\/revisions"}],"predecessor-version":[{"id":576553,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390295\/revisions\/576553"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}